Fentanyl Criminalization Bill Headed To Trump’s Desk Also Makes It Easier To Study Marijuana, Congressman Says

Congress has passed a bill that is primarily focused on permanently banning
analogues of fentanyl, though it also contains provisions that one GOP
lawmaker said would remove barriers to conducting research into the risks
and benefits of marijuana and other Schedule I drugs.

The House passed the Halt All Lethal Trafficking of (HALT) Fentanyl Act in
a 321-104 vote on Thursday. The legislation cleared the Senate in March and
next heads to President Donald Trump’s desk.

The bill is virtually identical to a House version that was approved by the
chamber in February, drawing criticism from advocates who voiced concerns
about the primary intent to criminalize people over a wider array of
controlled substances.

But other components of the measure, as Rep. Morgan Griffith (R-VA)
explained on the floor on Wednesday, would streamline research into
Schedule I drugs like marijuana.

“What we did in this bill—and I think it’s something that everybody on the
floor can be proud of—is we put into this bill the capability to do
extensive research by our research universities, by the [National
Institutes of Health and] by the [Food and Drug Administration],” Griffith
said.

“This bill has the component parts to make that possible, unlike our
Schedule I on marijuana, which never allowed research, or realistic
research, and created some of the dilemmas that we have today with that
substance,” he said. “We fixed that with this bill.”

For advocates, the problem is with the crux of the legislation, which would
classify fentanyl-related substances as Schedule I drugs under the
Controlled Substances Act (CSA), including analogues that haven’t been
proven to carry the same risks as the most well-known potent opioid. They
say the scheduling action would increase mandatory minimum sentences,
reflecting an outmoded war on drugs mentality that would contribute to mass
incarceration.

This marks the third time the House has approved the HALT Fentanyl Act.

Maritza Perez Medina, director of federal affairs at the Drug Policy
Alliance (DPA), after House passage of the earlier version in February that
the “only thing the HALT Fentanyl Act will do is halt the health approaches
that our communities need to stay alive.”

“This counterproductive bill will block health solutions to the overdose
crisis, exacerbate racial disparities in the criminal legal system, and
lead to an even more potent, unknown drug supply,” she said.

Despite the bill’s main punitive-focused thrust, other provisions of the
HALT Fentanyl Act that aim to expedite registrations for studies into
Schedule I drugs such as cannabis.

Some of the research provisions of the bill are similar to those contained
in a marijuana-focused measure that former President Joe Biden signed into
law in 2022.

Under the legislation, a research applicant who is actively registered with
the Drug Enforcement Administration (DEA) to study Schedule I and II drugs
would need to have their request assessed within 30 days of sending a
notice to the Justice Department.

A non-registered applicant would have to have their submission considered
within 45 days of sending the notice.

The measure also states that research that’s being conducted or funded by
federal agencies like the U.S. Department of Health and Human Services
(HHS) would qualify for expedited processing.

Further, the bill says that duplicative registrations would no longer be
required for all researchers involved in an approved study of a Schedule I
substance if they’re all part of the same research institution.

However, while it would also provide for the limited manufacturing of
controlled substances by researchers, there’s a specific exemption for
cannabis with respect to the manufacturing provisions.

Louisiana Senate Votes To Create Psychedelics Task Force Focused On
Benefits For Military Veterans

The post Fentanyl Criminalization Bill Headed To Trump’s Desk Also Makes It
Easier To Study Marijuana, Congressman Says appeared first on Marijuana
Moment.